Moderna delivers Canada’s first locally manufactured mRNA vaccines
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Merck opens first climate-neutral manufacturing facility in Ireland
The lab will facilitate the development of herbal and natural-based solutions
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
Subscribe To Our Newsletter & Stay Updated